Bioporto Valuation Multiples

Bioporto Overview

About Bioporto

Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.

Founded

2000

HQ

Employees

31

Website

bioporto.com

Sectors

Medical Imaging & DiagnosticsHealthTech

Financials (LTM)

Revenue: $6M

EBITDA: ($12M)

EV

$66M

Valuation Multiples

Multiples.vc

Start free trial

Bioporto Financials

Bioporto reported last 12-month revenue of $6M and negative EBITDA of ($12M).

In the same LTM period, Bioporto generated $5M in gross profit, ($12M) in EBITDA losses, and had net loss of ($9M).

Bioporto P&L

In the most recent fiscal year, Bioporto reported revenue of $6M and EBITDA of ($13M).

Bioporto expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bioporto Stock Performance

Bioporto has current market cap of $74M, and enterprise value of $66M.

Bioporto's stock price is $0.15.

Bioporto Valuation Multiples

Bioporto trades at 10.5x EV/Revenue multiple, and (5.5x) EV/EBITDA.

Bioporto Financial Valuation Multiples

As of April 19, 2026, Bioporto has market cap of $74M and EV of $66M.

Equity research analysts estimate Bioporto's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bioporto has a P/E ratio of (7.9x).

Bioporto Margins & Growth Rates

Bioporto's revenue in the last 12 month grew by 19%.

Bioporto's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.

Bioporto's rule of 40 is (141%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bioporto's rule of X is (134%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Bioporto Public Comps

See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.

Bioporto M&A Activity

Bioporto acquired XXX companies to date.

Last acquisition by Bioporto was on XXXXXXXX, XXXXX. Bioporto acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bioporto Investment Activity

Bioporto invested in XXX companies to date.

Bioporto made its latest investment on XXXXXXXX, XXXXX. Bioporto invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).